1. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
   null null et al, 2016, International Journal of Clinical Oncology CrossRef
2. Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study
   Shunsuke Kato et al, 2018, The Tohoku Journal of Experimental Medicine CrossRef
3. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
   null null et al, 2017, Cancer Chemotherapy and Pharmacology CrossRef
4. XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
   Ayse Ocak Duran et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef